Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.56 +5.13%

+$0.08 today

Market cap
$381.13M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 1.27M

Average 0.65M

ALEC Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Alector, Inc.NASDAQ: ALEC

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -2192.2%

Net margin was -2192.2% in Q1 FY2026, down 1090.6 pp from a year earlier. On a trailing-twelve-month basis it was -680.8%, down 541.1 pp year over year. Over 3 fiscal years it narrowed by 579.4 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of 56.1% for the fiscal year ending Dec 2026, up from -679.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-2192.2%-1594.6 pp QoQ
Last fiscal yearDec 2025
-679.2%-560.8 pp YoY
LTMMar 2026
-680.8%-541.1 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1090.6 pp-1112.9 pp-22.3 pp
1 year-560.8 pp+735.2 pp+1296.0 pp
3 years-579.4 pp-62.9 pp+516.5 pp
5 years+131.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-679.2%
Year-over-year change
-560.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ALEC compares with its peers on the latest reported figures

  • ALEC's LTM Mar 2026 net margin of -680.8% is the highest of the 3 companies compared; the peer median is -1474.6%.
  • Its year-over-year change of -541.1 pp is the 2nd highest of 3, against a peer median of -600.4 pp.
  • Over three fiscal years its change of -579.4 pp compares with a peer median of -1076.4 pp.
ALEC Competitors Peer median
Net Margin for ALEC and competitors
Company Period LTM level YoY 3-year change
ALECAlector, Inc.LTM Mar 2026-680.8% -541.1 pp-579.4 pp
IRDOpus Genetics, Inc.LTM Mar 2026-892.4% -462.9 pp-394.2 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2056.8% -737.9 pp-1758.5 pp
VORVor Biopharma Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
NKTXNkarta, Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ALEC) -1474.6%-600.4 pp-1076.4 pp

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.